- Home
- IMMX vs BYSI Comparison
IMMX vs BYSI Comparison
Compare IMMX & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- BYSI
- Stock Information
- Founded
- IMMX 2014
- BYSI 2010
- Country
- IMMX United States
- BYSI United States
- Employees
- IMMX N/A
- BYSI N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- BYSI Health Care
- Exchange
- IMMX Nasdaq
- BYSI Nasdaq
- Market Cap
- IMMX 61.1M
- BYSI 71.0M
- IPO Year
- IMMX 2021
- BYSI 2017
- Fundamental
- Price
- IMMX $2.65
- BYSI $2.29
- Analyst Decision
- IMMX Strong Buy
- BYSI
- Analyst Count
- IMMX 1
- BYSI 0
- Target Price
- IMMX $7.00
- BYSI N/A
- AVG Volume (30 Days)
- IMMX 137.1K
- BYSI 126.0K
- Earning Date
- IMMX 08-11-2025
- BYSI 08-11-2025
- Dividend Yield
- IMMX N/A
- BYSI N/A
- EPS Growth
- IMMX N/A
- BYSI N/A
- EPS
- IMMX N/A
- BYSI N/A
- Revenue
- IMMX N/A
- BYSI N/A
- Revenue This Year
- IMMX N/A
- BYSI N/A
- Revenue Next Year
- IMMX N/A
- BYSI N/A
- P/E Ratio
- IMMX N/A
- BYSI N/A
- Revenue Growth
- IMMX N/A
- BYSI N/A
- 52 Week Low
- IMMX $1.26
- BYSI $0.98
- 52 Week High
- IMMX $3.00
- BYSI $3.44
- Technical
- Relative Strength Index (RSI)
- IMMX 61.44
- BYSI 48.99
- Support Level
- IMMX $2.16
- BYSI $2.20
- Resistance Level
- IMMX $2.80
- BYSI $2.42
- Average True Range (ATR)
- IMMX 0.17
- BYSI 0.22
- MACD
- IMMX 0.04
- BYSI -0.08
- Stochastic Oscillator
- IMMX 80.00
- BYSI 9.68
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.